Neurocrine to discuss movement disorder program data Sept. 10 – 16

Neurocrine Biosciences (NASDAQ:NBIX) will present new data as part of 30 abstracts accepted from its movement disorder programs for tardive dyskinesia (TD) and Parkinson’s disease at the virtual scientific meetings, 2020 Psych Congress on September 10–13 and the MDS Virtual Congress 2020 on September 12–16.

Key highlights include data analyses from long-term Phase III studies of INGREZZA (valbenazine) capsules in adult patients with TD demonstrating sustained clinical benefit, safety and tolerability;

New Phase III data analyses of ONGENTYS (opicapone) capsules in patients with Parkinson’s disease, and;

Phase Ib data of an investigational gene therapy, NBIb-1817 (VY-AADC), evaluating outcomes of patients with advanced Parkinson’s disease.

Tardive dyskinesia is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face and other body parts.

https://seekingalpha.com/news/3611698-neurocrine-bio-to-discuss-data-from-movement-disorder-programs-scientific-meetings-sept-10-16